NCI Community Oncology Research Program
A program of the National Cancer Institute of the National Institutes of Health

CRO Communiqué
Keeping you informed about CRO progress

August 2016

Cancer Research for the Ozarks

Top Enrolling Physicians for July 2016

Physician	Patient Registrations	Treatment Credits	Control Credits	Total Credits	Registered Exceptional Responders
Dr. Becthel (Mercy St. Louis)	2	1.1		1.1	
Dr. Bonebrake (Cox)	1	1		1	
Dr. Carlson (Mercy Spfld)	1	1		1	
Dr. Craft (Mercy St. Louis)	1		0.0125	0.0125	
Dr. Donegan (Mercy St. Louis)	2	1.175	0.25	1.425	
Dr. Miller (Freeman)	1	0.3375		0.3375	
Dr. Oza (Good Samaritan)	2		1.0125	1.0125	
Dr. Raju (Mercy Spfld)	1	0.2625		0.2625	
Dr. Sleckman (Mercy St. Louis)	1	0.2625		0.2625	`
Dr. Snider (Mercy Spfld)	1	0.3375		0.3375	
Dr. Tiriveedhi (Mercy Spfld)	2	2.125		2.125	
TOTALS	15	7.6	1.275	8.875	

CRO had 12 registrations equaling 8.875 credits this month. This ends our second NCORP grant year. Yearly statistics are being gathered and will be shared in our CRO annual report being compiled at this time.

CRO Website Update

CRO's updated website went live on 7/27/16. Our website now includes trial schemas and eligibility criteria, a new patient education component and has a brighter look. Here is the link to our updated website http://ozarkscancerresearch.org/ Please take a look.

CRO Marketing

Marketing departments at CoxHealth and Mercy Springfield are working with CRO to produce marketing material for 30-sec TV and Radio ads. Our goal is to educate our community regarding CRO services and thus increase trial enrollments.

Dr. John Bumberry Co-Author

CRO investigator, John Bumberry will be a co-author for EA study E4112 - Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma in Situ. Cancer Research for the Ozarks entered 15 patients and is entitled to an accrual author. Dr. Bumberry placed eight of CRO's enrolled fifteen patients on the trial. Congratulations Dr. Bumberry!!

Tissue + Blood NCI Administrative Supplement

CRO has submitted a grant request to NIH to participate in "PDX Supplement, Tissue + Blood (v3)" for the upcoming grant year 2016-2017. This procurement opportunity includes the collection of 36 paired tissue + blood submissions. We are eager to receive NIH's response.

Study Profile

E3612 "A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma" is this month's profile study. The purpose of this research study is to compare the effects, good and/or bad, of ipilimumab or in combination with bevacizumab in treating unresectable advanced melanoma. Ipilimumab is the standard treatment for advanced melanoma and it does a good job in treating melanoma (skin cancer). Bevacizumab is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is approved by the U.S. Food & Drug Adminstration(FDA)for treatment of other cancers but it's use in this study is experimental. This study is looking to see if the addition of bevacizumab to ipilimumab can further

improve treatment of melanoma. Participants must have unresectable (can't be removed surgically) advanced melanoma that has not been treated or has only received one treatment.

Judy Hancock is our Cancer Care Delivery Research Coordinator. Judy has been a practice manager for the past 22 years, most recently at Dr. Carlson's office. She is a licensed nursing home administrator. She holds a B.S. in Business Administration and a M.S. in Health Administration. We are very excited to have Judy join us on August 15, 2016.

Andrea Reaves

Andrea Reaves is our new regulatory coordinator. Andrea previously worked in research at Highlands Oncology Group in Fayetteville, Arkansas. Most recently she has worked at American National Insurance. Andrea will be with us at CRO on August 8th.

Sweath Mereddy

We are sad to have Swetha leave us at CRO but understand the strain her working in Springfield has been on her and her family who reside in Lincoln, Nebraska. Swetha's last day with was July 29th. CRO's Cancer Research Professional position is posted at both Cox & Mercy.

ACTIVATION OF CIRB Protocols:

None

ACTIVATION OF Local Protocols:

None

CIRB Protocols reactivated:

ECOG-ACRIN EA1131 "A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Closure through Local IRB:

Alliance A091305 – Temporary suspension A Phase 2 Randomized Study of Efatutazone, an Oral PPAR Agonist, in Combination With Paclitaxel Versus Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer

CIRB Closures:

GOG-0281 "A Randomized Phase II/III Study To Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer" - closed to accrual in US effective 6/29/2016

S1400C Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer **" – Arm C temporarily closed**

CIRB Studies – Follow up terminated:

NSABP B-38 "A Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Node-Positive Breast Cancer: Docetaxel/ Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC -> P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC -> PG)"